- HOME
- Vol.46 No.11
- CLINICA NEUROL, 46: 769－773, 2006
- Vol.46 No.11 contents
The 47th Annual Meeting of the Japanese Society of Neurology
Dopa-responsive dystonia
Yoshiaki Furukawa, M.D.
Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division
Dopa-responsive dystonia (DRD) is a clinical syndrome characterized by childhood-onset dystonia and a dramatic and sustained response to relatively low doses of levodopa. There are at least three causative genes for DRD: 1) the GCH1 gene on chromosome 14q22.1-q22.2, coding for the enzyme GTP cyclohydrolase I (GTPCH) that catalyzes the rate-limiting step in the tetrahydrobiopterin (BH4; the cofactor for tyrosine hydroxylase [TH]) biosynthesis, 2) the TH gene on 11p15.5, and 3) an as yet undefined gene on 14q13 (DYT14). In our series, 86% of families with DRD or dystonia with motor delay (an intermediate phenotype between GTPCH-deficient DRD [mild] and GTPCH-deficient hyperphenylalaninemia [severe]) had identifiable GCH1 or (rarely) TH mutations. Neurochemical data suggest that striatal dopamine reduction in GTPCH-deficient DRD (the major form of DRD) is caused not only by decreased TH activity resulting from a low cofactor level but also by actual loss of TH protein without nerve terminal loss. This TH protein reduction in the striatum (especially in the putamen) may be due to a diminished regulatory effect of BH4 on stability of TH molecules or to a dysfunction of TH protein transport from the substantia nigra to the striatum.
(CLINICA NEUROL, 46: 769－773, 2006)
key words: dopa-responsive dystonia, GTP cyclohydrolase I, tetrahydrobiopterin, tyrosine hydroxylase, DYT14 dystonia
(Received: 11-May-06)
